Reducing Xerostomia by Comprehensive Protection of Salivary Glands in Intensity-Modulated Radiation Therapy with Helical Tomotherapy Technique for Head-and-Neck Cancer Patients: A Prospective Observational Study

Abstract EN

Objective.

This study aimed to analyze the effects of comprehensive protection of bilateral parotid glands (PG-T), contralateral submandibular gland (cSMG), and accessory salivary glands in the oral cavity (OC) by helical tomotherapy for head-and-neck cancer patients.

Methods.

Totally 175 patients with histologically confirmed head-and-neck cancer treated with helical tomotherapy were recruited.

The doses delivered to PG-T, cSMG, and OC were constrained to be as low as possible in treatment planning.

The saliva flow rates and xerostomia questionnaire were evaluated.

Correlation between xerostomia and other clinical factors were assessed using univariate and multivariate models.

The impact of salivary gland dose on locoregional (LR) recurrence was assessed by Cox analysis.

ROC curve was used to determine the threshold of mean dose for each gland.

Results.

The median follow-up was 25 (19–36) months.

The OC mean dose, PG-T mean dose, cSMG mean dose, age, clinical stage (II and III versus IV), and both unstimulated and stimulated saliva flow rates were significantly correlated with xerostomia.

The OC mean dose, cSMG mean dose, age, and clinical stage were predictors of xerostomia after adjusting PG-T mean dose, and unstimulated and stimulated saliva flow rates.

Xerostomia was significantly decreased when the mean doses of PG-T, cSMG, and OC were kept below 29.12Gy, 29.29Gy, and 31.44Gy, respectively.

At 18 months after radiation therapy, early LR recurrence rate was only 4%.

Conclusion.

Comprehensive protection of salivary glands minimized xerostomia in head-and-neck cancer patients treated by helical tomotherapy, without increasing early LR recurrence risk.